Reflex sympathetic dystrophy" and "causalgia" are now classified by the International Association for the Study of Pain as Complex Regional Pain Syndromes I and II. Sympathetically maintained pain is a frequent but variable component of these syndromes, as the sympathetic and somatosensory pathways are no longer functionally distinct. Pain is the cardinal feature of CRPS, but the constellation of symptoms and signs may also include sensory changes, autonomic dysfunction, trophic changes, motor impairment and psychological changes. Diagnosis is based on the clinical picture, with additional information regarding the presence of sympathetically maintained pain or autonomic dysfunction being provided by carefully performed and interpreted supplemental tests. Clinical experience supports early intervention with sympatholytic procedures (pharmacological or nerve block techniques), but further scientific data is required to confirm the appropriate timing and relative efficacy of different procedures. Patients with recurrent or refractory symptoms are best managed in a multi-disciplinary pain clinic as more invasive and intensive treatment will be required to minimize ongoing pain and disability.
sympathetic dystrophy" and "causalgia" are now classified as Complex Regional Pain Syndromes (CRPS) I and II 1, 2 . CRPS can lead to severe ongoing pain and disability after relatively minor trauma.
TERMINOLOGY
In 1872, Mitchell described a syndrome of burning pain, hyperaesthesia, trophic changes with glossy skin and colour changes, in the limbs of American Civil War soldiers who sustained nerve injuries 3 . He later coined the term "causalgia" from the Greek "kausis" meaning burning, and "algos" meaning pain. Since that time an array of terms have been used by different medical disciplines in different countries, and include algodystrophy, Sudeck's atrophy, peripheral acute trophoneurosis, traumatic angiospasm or vasospasm, shoulder-hand syndrome, post-infarction sclerodactyly, sympathetically maintained pain and reflex sympathetic dystrophy (RSD).
In an effort to establish uniform terminology and diagnostic criteria, a consensus conference was convened by The International Association for the Study of Pain. The term "reflex sympathetic dystrophy" was felt to have lost clinical relevance as the term has been used indiscriminately, signs and symptoms vary with time, not all cases have predominantly sympathetically maintained pain leading to variable responses to sympathetic blockade, and dystrophic changes are not always present 2, 4 . A new taxonomy has been suggested in which the condition previously described as "RSD" is classified as Complex Regional Pain Syndrome (CRPS) Type I, and when associated with a nerve injury as CRPS Type II 1,2 , rather than "causalgia". CRPS was chosen as an overall term as clinical phenomena are varied and complex, symptoms occur in a regional distribution and pain is the cardinal symptom.
Definition
CRPS Type 1 is a syndrome that usually follows an initiating noxious event; spontaneous pain or allodynia/hyperalgesia occur in a regional distribution not limited to the territory of a single peripheral nerve, and the degree of pain is apparently disproportionate in severity to the inciting event. It is associated at some point with evidence of oedema, changes in skin blood flow or abnormal sudomotor activity in the region of the pain 1, 2, 4 . Unlike "RSD", these criteria do not allude to an underlying pathogenesis.
The criteria for CRPS Type 11 are the same as Type 1, but the syndrome develops in association with a nerve injury 3, 4 . The onset may occur immediately after partial nerve injury or be delayed for months 1, 5 . The nerves most commonly involved are the median, sciatic, tibial, and ulnar. "Causalgia" of the radial nerve is rare 1 .
CRPS is not limited to injuries involving the limbs. It may also develop in association with visceral diseases (due to involvement of intra-abdominal sympathetic nerves such as the coeliac plexus), central nervous system lesions, soft tissue lesions, "amputation" syndromes such as mastectomy, and may be a component of back pain.
Sympathetically maintained pain (SMP) is pain that is maintained by sympathetic efferent innervation or neurochemical or circulating catecholamine action. Pain relieved by a specific sympatholytic procedure (pharmacological or sympathetic nerve blockade) may be considered SMP, although the duration of pain relief will only be temporary in some cases. The proportion of sympathetically maintained pain may vary between patients, or with time in an individual patient, and the residual pain is termed sympathetically independent pain (SIP). SMP may be found in association not only with CRPS, but also other pain disorders including herpes zoster, phantom pain, and neuropathies 1, 2, 4 .
CLINICAL MANIFESTATIONS
CRPS consists of a constellation of symptoms and signs which may include pain and sensory changes, autonomic dysfunction, trophic changes, motor impairment, and psychological changes 4 .
(1) Pain. Pain is an essential criterion for CRPS and is disproportionate in duration, severity and distribution to that expected for the usual clinical course of the inciting event. Initial burning and distal pain becomes more diffuse and aching, and fluctuates in intensity. Hyperalgesia may be present, and allodynia to light touch, thermal stimulation, deep pressure or joint movement 1, 4, 6 . The relative contribution that SMP may have to the overall pain: A: a person whose pain is predominantly unresponsive to sympatholysis; B: a patient with pain that is almost totally sympathetically maintained. Points A and B may represent different patients or the same patient at different times. From: Boas RA. Complex regional pain syndromes: symptoms, signs, and differential diagnosis. In: Janig W, Stanton-Hicks M, eds. Reflex Sympathetic Dystrophy: A Reappraisal. Progress in Pain Research and Management Vol 6. IASP Press, Seattle 1996; p. 83.
(2) Autonomic dysfunction. Abnormalities of skin blood flow lead to changes in skin temperature and colour, ranging from warm and red to cold, pale and cyanotic. Oedema is objectively present in less than 50% of cases, but a higher proportion of patients describe swelling of the limbs which may represent abnormal sensory processing or a dysaesthesia. Sympathetically generated vasoconstriction on the postcapillary venules which exceeds arterioconstriction on the precapillary vessels may result in oedema due to an increased filtration pressure 7 . Alternatively, neuropeptide release from sympathetic postganglionic neurons 8 or from primary afferent nociceptors 9 may mediate oedema. Increased or decreased sweating may occur with side-to-side asymmetry between affected and non-affected limbs.
(3) Trophic changes. Trophic changes are not invariably present. Muscle wasting, thin shiny skin, coarse hair and thickened nails are often late manifestations. Joint stiffness may occur due to functional motor disturbances (decreased muscle strength or flexor-extensor contractions), and/or trophic changes in joints and tendons 1, 5, 10 . Use of the term Sudeck's atrophy was based on the finding of osteoporosis, but this sign is non-specific and occurs in only a small percentage of cases.
(4) Motor impairment. Impairment of motor function, including weakness, tremor and dystonia may occur, but are not included in the essential criteria for CRPS. Voluntary guarding may be seen as patients attempt to protect their hyperalgesic limb, and range of movement will be limited by pain. Alternatively, a central nervous system neglect-like syndrome has also been postulated as the cause of motor impairment 11 .
(5) Psychological issues. Psychological factors play a role in all forms of pain and dysfunction, as they influence patients' beliefs, expectations, incentive for recovery, coping mechanisms and stress tolerance. Behavioural responses are particularly important in patients with CRPS as immobilization and overprotection of the affected limb may produce or exacerbate demineralization, vasomotor changes, oedema and trophic changes. As symptoms are disproportionate to the injury and the pathophysiology is ill-defined, maladaptive behaviours may be misinterpreted as indicating psychopathology 12, 13 . The view that "RSD" is predominantly a psychological disorder has been presented by Ochoa and Verdugo 14 .
They question the role of the sympathetic nervous system in the generation of pain states, and attribute the clinical picture of CRPS 1 patients to pseudoneuropathy of psychogenic origin. Issues of secondary gain such as workers' compensation have also been used to explain disproportionate symptoms. Covington suggests that "much disability in injured workers may be due to 'the system' that challenges the validity of patients' complaints and introduces harmful delays in treatment" 12 . There is no evidence from current series that a particular psychological profile predisposes to CRPS, and most authors conclude that behavioural and emotional changes are a result rather than a cause of pain.
Incidence
The lack of uniform terminology and diagnostic criteria makes it difficult to determine the incidence of CRPS. Veldman et al 15 reported CRPS occurring in 1 to 2% of patients after fractures, and 2 to 5% after peripheral nerve injury. There is no correlation between the severity of the initial injury and the likelihood of CRPS developing, and in 10 to 26% of cases no precipitating cause can be ascertained 15, 16 . The incidence of CRPS following Colles' fracture has been reported from 7 to 35% 17 . In a prospective study in Britain, 274 patients with Colles' fractures were assessed 18 . Two weeks following removal of the plaster cast, 54% of patients had one or more features of CRPS as judged by bone pain or tenderness, vasomotor symptoms, finger stiffness, and swelling of the hand. Twenty-eight per cent of patients had all four features, and were designated as the CRPS group, but none received treatment specific for CRPS. All patients were then reassessed monthly until the symptoms had abated, or up to six months in the case of asymptomatic patients. Many patients improved rapidly, but vasomotor symptoms and finger stiffness were slower to resolve. The authors cautioned against attributing symptom resolution to early treatment, as the natural history of CRPS suggests spontaneous resolution in many patients. However, six months following the fracture, pain and swelling persisted in 20 to 30% of the CRPS group, 50% had vascular instability and tenderness and 80% had residual stiffness. Thus, there was appreciable short-term morbidity and loss of function in many patients following Colles' fracture.
Differential Diagnosis
The differential diagnosis for a hot, red, painful extremity includes unrecognized local pathology (e.g. fracture, strain, sprain), septic arthritis, cellulitis and allergy. A cold blue atrophic limb may result from vascular insufficiency (Raynaud's disease, thromboangitis obliterans, thrombosis) or disuse and immobilization 1,6 .
Stages
"RSD" was traditionally divided into stages -Stage 1: acute (pain and oedema); Stage 2: dystrophic (muscle wasting, pale cyanotic skin); and Stage 3: atrophic (bone and skin changes ). The value of staging is questionable as the duration of the first two stages is variable and it is not possible to predict who will progress to the third atrophic stage 1, 19 . Prolonged disuse of affected limbs due to pain and guarding increases atrophic changes.
CRPS in Children
CRPS occurs in children but is under-recognized, and often diagnosed late. Wilder et al 20 reported 70 children with CRPS and the average time to diagnosis was twelve months. Prior to the diagnosis of CRPS, symptoms may be attributed to a variety of conditions, resulting in unnecessary use of invasive investigations, and inappropriate treatments such as immobilization with plaster casts and non-weight-bearing.
In adults, upper limb involvement is most common, but in children the lower extremity is more frequently involved 21, 22, 23 (84% of 395 cases reviewed 24 , and 90% of 41 cases from Royal Children's Hospital, Melbourne). There is also a marked predominance of affected females to males (4:1 24 ) in paediatric cases. The peak incidence is between 9 and 13 years of age but CRPS Type II has been reported in a three-yearold 25 .
The prognosis for CRPS in children is more favourable as few progress to atrophic changes or osteoporosis 21, 23 . Resumption of weight-bearing is imperative and the use of crutches and wheelchairs should be discouraged as disuse will increase symptoms and can lead to retardation of bone growth in longstanding cases 26 . The main role of imaging is to exclude other diagnoses, e.g. stress fracture, infection, osteoid osteoma and other tumours 20 .
Psychological disturbances have been recognized in children with CRPS 27,28 , but there is no evidence that a particular psychological profile predisposes to the development of this syndrome. Many of the adolescent patients are involved in competitive activities such as gymnastics, team sports or dance. These children may be more likely to suffer musculoskeletal injuries, but it has also been suggested that their pain offers an acceptable escape from competitive sport and parental expectations 22, 27 . The patient and family members should be involved in assessment and treatment, as goals of therapy include relief of pain as well as return of function and attendance at school.
Sympathetic blocks have a role in children with CRPS, to provide pain relief and allow physiotherapy and mobilization. The timing of invasive procedures in children is debated. Olsson 21 reported complete recovery in 60% of patients and improvement in a further 25% of 55 children who underwent intravenous regional block with guanethidine for CRPS. However, the duration of followup is not stated, and some patients were excluded from the treatment group. In contrast the treatment algorithm of Wilder et al 20 emphasizes physiotherapy, TENS, and cognitive behavioural pain management techniques as the first line of treatment, with addition of a tricyclic antidepressant if symptoms are inadequately controlled. Sympathetic blocks are reserved for patients unresponsive to non-invasive therapies who are unable to tolerate physiotherapy due to pain. Sympathetic blocks were associated with the highest rate of reso- lution of symptoms but were required in only 37 of the 70 patients. No correlation was found between the duration of symptoms and the likelihood of relief of symptoms following a sympathetic block, but it should be remembered that these children had longstanding symptoms (average 12 months) prior to diagnosis. At three-year followup, 43 of the 70 patients still had pain although this had reduced in severity from an average visual analog pain score of 8.7 to 5 out of 10. Of those previously involved in sports only half had resumed their activity. Thus, a significant proportion of children with CRPS will require a longterm management plan.
Recurrent CRPS
Recurrent episodes of CRPS occur in 10 to 30% of patients 16, 19 and migratory symptoms involving multiple extremities have also been reported 16, 19, 29, 30 . In a review of 1183 patients by Veldman and Goris 16 , recurrent "RSD" was recognized in 10% of patients with the time between initial and second episode ranging from 3 months to 20 years (median 2.7 years). Diffuse pain often preceded the onset of more typical signs and symptoms and in half of the patients no precipitant for the recurrence was identified. Recurrences were more common in the symmetrical limb of younger patients.
Dielissen et al 31 recently reviewed the results following amputation for "RSD". Twenty-eight patients had 34 amputations (three patients had two limbs amputated and three had had two amputations on one limb). The amputations had been performed for "untenable pain" (authors' description) in five patients, recurrent infection in 14 patients or to improve residual function in 15 patients. Only two patients had complete relief of pain after the amputation and thirteen patients had increased pain. Recurrence of "RSD" in the stump occurred following 28 amputations, and was further complicated by phantom sensation in 29 cases and phantom pain in 24 cases. Prostheses were fitted for twenty-two patients with proximal amputations, but twenty patients could not tolerate the prosthesis due to recurrent "RSD" or stump hyperalgesia. Nine of the fifteen patients who had undergone amputation with the aim of improving residual function thought that this had been achieved. In this series, the use of epidural anaesthesia (sixteen cases) did not influence the rate of postoperative phantom pain or recurrence of "RSD", although the duration of treatment and agents used is not specified.
A racial difference with a higher incidence of CRPS in Caucasian populations has been found in some series. These observations have led to the hypothesis that a genetic predisposition to CRPS may exist. Mailis and Wade 32 performed human lymphocyte antigen (HLA) analysis on 15 women attending a university pain clinic. A twofold increase of A3, B7, and DR2(15) MHC antigens was found in the study population compared to controls. Five of the six DR2(15)-positive patients were resistant to treatment. Multiple sclerosis has also been associated with DR2 (15) . Study of larger patient groups with CRPS are required to support this initial finding.
PATHOPHYSIOLOGY
The pathophysiology of CRPS is not yet fully elucidated. Central and peripheral sites for coupling between sympathetic and somatosensory pathways have been suggested. Current information is based on a combination of animal research and clinical observations.
Peripheral Mechanisms
Nociceptors are normally unresponsive to noradrenaline. In CRPS, both direct and indirect methods of excitation of nociceptors by noradrenaline have been proposed. Following nerve damage, a subset of C-polymodal nociceptors have been shown to develop sensitivity to sympathetic stimulation 33 and thus may be directly stimulated by noradrenaline. Alternatively, noradrenaline may act indirectly via release of prostaglandins which stimulate the nociceptor. Under pathological conditions, noradrenaline released from sympathetic postganglionic neurones (SPGN) can stimulate release of prostaglandins 34, 35, 36 . Following sciatic nerve injury in rats, hyperalgesia was exacerbated by peripheral injection of noradrenaline (suggesting sympathetically maintained pain), and eliminated by peripheral injection of indomethacin (suggesting mediation by prostaglandins). The α 2 -adrenergic receptor is involved as injection of the non-specific α-adrenergic blocker phentolamine and the α 2 -adrenergic blocker yohimbine significantly relieved the hyperalgesia, while injection of the α 1 -blocker prazosin had no effect 35 . The increased response to noradrenaline associated with nerve damage may be secondary to up-regulation of the density or affinity of α 2 -adrenoreceptors located on the SPGN 35 , or amplification of the intracellular effects of these receptors due to an increase in intracellular calcium 36 .
The animal studies above are based on a model of nerve injury with associated SMP (hyperalgesia is relieved by sympathectomy) 35, 37 . These studies most closely relate to CRPS II, and it is assumed that CRPS I shares similar or overlapping pathophysiological mechanisms. However, inflammation may also induce nociceptor sensitivity to noradrenaline. Sanjue et al 38 showed weak activation of polymodal nociceptors by sympathetic stimulation in the resting state, but marked facilitation when the nociceptors were in a state of sustained discharges. This increased sensitivity only occurred after local administration of an algogenic compound (containing serotonin, histamine, potassium chloride and sodium hydrochloride) suggesting indirect stimulation via a chemical mediator. SMP could thus be postulated to occur if inflammation persisted or C-nociceptor responsiveness to noradrenaline did not disappear with healing 37 .
Central Mechanisms
Central mechanisms have been proposed to explain the development of hyperalgesia and more generalized pain in patients with CRPS. The plasticity of pain transmission pathways 39 with changes in receptor sensitivity, genetic changes in dorsal horn neurones and neuro-anatomical re-organization can lead to central sensitization and "wind-up". C-polymodal nociceptors activate and sensitize widedynamic range (WDR) neurones in the dorsal horn. The sensitized WDR neurones then respond to activity in large diameter A-mechanoreceptors which are activated by light touch. The pain threshold is reduced and previously subthreshold stimuli are then perceived as painful (i.e. hyperalgesia). Roberts 40 hypothesized that in sympathetically maintained pain the A-mechanoreceptor activity is then maintained by sympathetic efferent action, in the absence of cutaneous stimulation. He subsequently showed that sympathetic activation of WDR neurones could be abolished by subcutaneous injection of local anaesthetic, cooling of the receptive field, and intravenous injection of the α-blocker phentolamine 41 .
After nerve damage, noradrenergic perivascular axons have been shown to sprout into the dorsal root ganglion and form basket-like structures around large diameter sensory neurones 42 . Thus sympathetic stimulation could repetitively activate sensory neurones, and this is another potential site of coupling between the somatosensory and sympathetic systems.
DIAGNOSTIC TESTS
A wide range of tests have been used to determine the presence of autonomic dysfunction and sympathetically maintained pain in patients with suspected CRPS. However, there is little data on the sensitivity and specificity of these tests; some are available only in specialized settings and interpretation of the results may be difficult. Diagnosis must be based on clinical symptoms and signs, with additional information being provided by carefully performed and interpreted supplemental tests.
Sympathetically Maintained Pain
The diagnosis of sympathetically maintained pain is made when the pain is relieved by sympathetic blockade. However, no single test has adequate sensitivity and specificity to conclusively distinguish between SMP and SIP. Possible tests include:
(1) Sympathetic ganglion block with local anaesthetic. Isolation of sympathetic from sensory nerve block is required by local anaesthetic blockade of sympathetic ganglia. The sympathetic chain receives efferent preganglionic fibres in the ventral roots of T1 (first thoracic nerve root) to L2 (second lumbar nerve root), and forms the stellate ganglion supplying head and neck and upper limb, thoracic paravertebral chain supplying thorax and contained viscera, coeliac plexus supplying gastrointestinal tract and abdominal viscera, lumbar paravertebral chain supplying distal colon and lower limb, and superior hypogastric plexus and ganglion impar supplying pelvic organs 43 the most common sites for sympathetic block. False negative results may occur due to technical failure of the block. In particular, blockade of all sympathetic fibres to the upper arm may not be achieved with a stellate ganglion block at C6, and paravertebral upper thoracic block or interpleural administration with the patient in a head-down position have been advocated to ensure spread of local anaesthetic solution to the upper thoracic nerve roots. False positive results may relate to spread of local anaesthetic to somatic fibres in nearby nerve roots 19 . Also sensory fibres from many deep somatic elements (costovertebral joint, posterior and anterior longitudinal ligaments, annular ligament of the intervertebral disc, dura) traverse the sympathetic rami and chain. Thus deep somatic pain transmitted by sympathetic pathways may be relieved by sympathetic blocks. Systemic uptake of local anaesthetic may also contribute to analgesia if large doses are administered. Low concentrations of lignocaine have a selective action on nociceptive transmission in the spinal cord which is different and more potent than its local anaesthetic action in the periphery. This includes a reduction of direct and synaptically driven NMDAand neurokinin receptor-mediated post-synaptic depolarizations 44 .
(2) Intravenous regional block with guanethidine. Guanethidine is taken up into the sympathetic nerve terminal and causes initial release of noradrenaline before the more longterm effect of depletion of noradrenaline (which persists for up to two days). Burning pain on injection due to noradrenaline release has been suggested as an indicator of SMP. A negative test does not exclude sympathetic-afferent coupling proximal to the cuff, i.e. spinal cord or central changes 19 .
(3) Intravenous phentolamine (α-adrenergic receptor antagonist). Analgesic response to intravenous infusion of phentolamine has been shown to be predictive of pain reduction following subsequent sympathetic blocks 21, 45, 46 . This technique has advantages as a diagnostic procedure as blinded placebo controlled infusions can be administered. It is relatively non-invasive and not painful and therefore more readily accepted by patients including children 21 . Blood pressure, heart rate, and visual analog pain scores are monitored. Blinded infusion of placebo and 15 mg phentolamine over 10 minutes in adults (5-10 mg in children) 45 has been proposed; or alternatively boluses of placebo followed by increasing doses of phentolamine (1+2+4+8+10 mg, and a further 10 mg if no cardiovascular changes) 46 . Recently, doses of 0.5 mg/kg to 1 mg/kg phentolamine over 10 to 20 minutes have been suggested by Raja et al 47 as measures of temperature change suggested that higher doses were required to adequately block α-adrenoceptor function. The specificity of this test has been questioned as phentolamine may have additional minor actions due to potassium channel blockade and direct smooth muscle relaxation.
Autonomic Assessment
Autonomic dysfunction can be detected by changes in skin temperature (thermography and thermometry), blood flow (cutaneous Doppler measurements, transcutaneous oxygen tension), resting sweat output (quantitative sudomotor axon reflex test), and the presence of oedema (volume displacement methods) 6 . These tests are predominantly used in an experimental or research setting.
Imaging
Imaging provides supporting information, but changes are non-specific and in longstanding cases may be partially attributed to disuse. Periarticular osteoporosis in long bones and diffuse osteoporosis in small bones may be seen on plain radiographs; and comparison with films of the unaffected limb is required. Three-phase bone-scanning measures uptake of radionuclide tracer at seconds (arterial phase), minutes (soft tissue phase), and hours (mineral phase) after intravenous injection. A diffuse increase in tracer uptake may be seen in the affected limb 19, 29, 30 , but a normal scan does not exclude the diagnosis of CRPS. In children, results are more variable, and a decrease rather than an increase in isotope uptake is more frequently seen 48, 49 . Magnetic resonance imaging demonstrated skin thickening and tissue enhancement with contrast material in 31 of 35 patients with warm painful limbs attributed to CRPS. Six patients also had soft tissue oedema. In patients with cold painful limbs, skin thickening or thinning was demonstrated, and four of five patients designated as "stage three" had muscle atrophy 50 .
Placebo Response
Diagnostic and therapeutic interventions for patients with chronic pain may be affected by a placebo response. Environmental and situational factors such as previous responses to treatment, patient cognitive factors relating to the need for and expectation of pain relief, and the expectations of the clinician administering the treatment can all influence the placebo response. The number of placebo responders is generally quoted as 33% 14 , but this varies markedly from 0 to 100% depending on the circumstances of the study 51 . In patients with CRPS, debate continues about the efficacy of sympatholytic procedures, as results may be enhanced by natural resolution of the disease 18 or by placebo responses 14 . Patients with chronic severe pain have a high desire for relief, and elaborate or invasive sympathetic blocks may be associated with high expectations. Placebo effects should be measured in comparable patient groups in well-controlled studies. Responses in individuals are more difficult to interpret and require comparison of the duration of response to both placebo and active treatments 52 .
TREATMENT
Early recognition and treatment are associated with the best chance of a successful outcome in patients with CRPS 10 . Treatment must include adequate management of the precipitating injury to minimize ongoing nociceptive stimulation from traumatized tissue, inflammation or infection. An active physiotherapy program is essential to preserve and recover limb function, increase circulation and bone mineralization, and therefore minimize secondary effects due to disuse. For upper limb involvement, therapy including scrub and carry movements are often used, with gradual increases in the weight of objects carried. In patients with lower limb involvement, weight-bearing is particularly important. There is widespread agreement about the importance of treating the precipitating injury and active physiotherapy, but conflicting evidence regarding subsequent treatment.
Intravenous Regional Blocks (IVRB)
Intravenous regional blocks have been widely used in the management of CRPS as they are relatively simple to perform. Following placement of a venous cannula, which may be difficult in a hyperaesthetic and oedematous limb, a tourniquet is inflated to suprasystolic pressures and the analgesic agent is injected. Use of a torniquet alone may influence subsequent pain. Campbell et al 53 reported relief of hyperalgesia four to twenty minutes after inflation of a suprasystolic pressure cuff, and proposed that hyperalgesia was mediated via A-β mechanoreceptor fibres which are more susceptible to pressure block than A-δ or C fibres (temperature sensation was not altered).
Guanethidine blocks re-uptake of noradrenaline and depletes peripheral adrenergic neurone stores. Incremental improvements in objective findings of dolorimetry, grip strength, finger stiffness and finger swelling have been shown with a series of four IVRB with guanethidine 54 . However, recent studies have questioned the efficacy of guanethidine in the management of CRPS 55, 56 . Jadad et al 55 identified four randomized controlled trials using guanethidine and none showed significant difference in analgesic response between the IVRB with guanethidine and control. As the authors noted these trials were hampered by poorly defined diagnostic criteria, inadequate washout periods, incomplete crossover, open administration of treatments, and a high proportion of withdrawals. A subsequent double-blind crossover study by Jadad et al 55 of nine patients who had previously responded to an open guanethidine IVRB failed to find a significant difference between guanethidine and placebo on any outcome measures, and there was no evidence of a dose response for guanethidine. In another double-blind study, sixty patients were randomized to receive one, two, or four blocks with guanethidine 56 . Short-term outcome showed no statistical difference in pain rating index in patients receiving IVRB with saline and lignocaine compared to those receiving guanethidine and lignocaine. The reduction in pain seen with the "control" blocks may have been contributed to by placebo response, the use of lignocaine, or effects of the tourniquet. All patients had at least one guanethidine block, but no greater degree of pain relief was seen in patients receiving four guanethidine blocks when compared to those receiving only one block with guanethidine. All treatment groups showed a decrease at the terminal visit in the number of patients with oedema, sudomotor changes, trophic changes, and vasomotor changes. Range of motion measurements indicated that most patients did not experience a clinically significant improvement over baseline, but it is not clear from the article if patients received any active physiotherapy or instruction regarding exercise of the affected limb. Overall, the authors stated that only 35% of patients experienced clinically significant relief (defined as overall improvement of 9 or 10 on patient global evaluation), and felt there was little evidence of a beneficial effect of guanethidine in IVRB.
Other agents have also been assessed in IVRBs. Bretylium 57 , which is taken up by adrenergic nerve terminals and reduces release of noradrenaline, and ketanserin 58 , a selective serotonin type 2 receptor antagonist, resulted in greater pain reduction than control in double-blind trials. Seven patients with features of CRPS and response to previous sympathetic blocks experienced significant relief of pain following IVRB with the non-steroidal antiinflammatory agent ketorolac 60 mg 59 . The duration of response tended to increase with subsequent blocks. The authors suggested that ketorolac may have beneficial effects due to reduction of prostaglandin release and also by interfering with the vasoconstriction produced by thromboxane. No statistically significant difference in reported pain intensity was found between intravenous regional block with clonidine or placebo 60 , despite evidence of an effective sympathetic block (measured by diminished vasoconstrictor ice response).
Sympathetic Ganglion Block
Procedures for blocking sympathetic supply to the upper limb at the stellate ganglion and to the lower limb at the lumbar sympathetic chain have been well described 43 . Early sympathetic blockade has been advocated in the adult literature 10 and may improve longterm outcome 61 . The efficacy of sympathetic ganglion blockade is difficult to determine due to limitations in the current literature (no standard diagnostic criteria, techniques of sympathetic block differ, and outcome assessment and duration of followup are variable). Improvement with early intervention may be partially attributable to the natural resolution of symptoms, or a placebo response to treatment. There are no controlled trials to support or discount these hypotheses, and such studies would be difficult to perform in a blinded fashion as sympathetic blocks are associated with clearly observable effects (e.g. Horners syndrome). Wang et al 61 studied 71 patients with CRPS over three years and compared pain ratings between two groups. Twenty-seven patients were managed conservatively, and after three years 41% showed signs of improvement. A second group of 43 patients were treated with sympathetic blocks and 65% had improved after three years. Kozin 62 reviewed seven studies of over 500 patients treated with sympathetic blocks and found approximately 46% of patients had satisfactory pain relief of prolonged duration.
The role of neurolytic and surgical sympathectomies is not clear. Often minimal or short-term improvements are achieved 10,63 despite the greater risk of complications associated with more invasive, destructive procedures. Radiofrequency lumbar sympatholysis has been described for patients with previous responses to sympathetic blocks 65 . Five patients continued to be pain free five months to three years after the last radiofrequency sympatholysis, but fifteen patients had only temporary or no relief of pain.
Regional Local Anaesthetic Block
Limb mobility and function may be reduced by guarding due to pain or by secondary effects of tendon shortening and joint stiffness. The passive range of movement of an affected limb may be more adequately assessed following regional local anaesthesia which provides motor, sensory, and sympathetic block. Patients with symptoms and signs unresponsive to intermittent sympathetic block may benefit from continuous local anaesthetic blockade for several days. Infusion of local anaesthetic via brachial plexus catheters is successful in some patients with upper limb CRPS and lumbar paravertebral catheters have been used to provide repeated lumbar sympathetic block 20 . In resistant cases, central sensitization is well-established and treatment at a spinal cord level with cervical or lumbar epidural infusions is often required. Careful monitoring and supervision of patients with cervical epidural local anaesthetic infusions is essential. Dilute concentrations of local anaesthetic should be used to minimize motor block, as the role of the epidural infusion is to provide analgesia and also facilitate active physiotherapy.
Clonidine
Clonidine, an α 2 -adrenergic agonist, has a potential therapeutic role in patients with CRPS via several mechanisms. Centrally, clonidine reduces sympathetic activity in the brainstem and this is the proposed site of action of oral clonidine as an antihypertensive agent. Currently, there is no consistent benefit shown for oral clonidine in CRPS as doses are often limited by systemic side-effects (hypotension and sedation). In the periphery, clonidine acts at prejunctional α 2 receptors to reduce noradrenaline release. When applied to limbs with CRPS, transdermal clonidine specifically reduces pain and hyperalgesia, but only in the localized area of application. This is not a local anaesthetic action as touch threshold is unchanged 64 . Intradermal injection of noradrenaline, in doses too low to have a systemic effect, rekindles pain following transdermal clonidine or sympathetic blocks. In the spinal cord, clonidine has been shown to enhance the activity of descending noradrenergic pathways which inhibit pain transmission in the dorsal horn. Epidural clonidine has been reported as an effective treatment for refractory CRPS. Rauck et al 66 reported twenty-six patients with CRPS of mean duration 45.7 ± 36 months, whose symptoms had not fully resolved with sympathetic blocks. Cervical or lumbar epidural catheters were inserted for patients with upper or lower limb CRPS respectively. Bolus doses of epidural clonidine 300 and 700 µg, but not placebo, were associated with a reduction in visual analog pain scores. Both doses were associated with reductions in blood pressure and heart rate, and the higher dose (700 µg) was also associated with sedation. Nineteen patients proceeded to continuous epidural infusions of clonidine (10-50 µg/hour) and obtained sustained analgesia. Duration of treatment ranged from 7 to 225 days with a mean of 43 days. Infections occurred in four patients with temporary catheters at 12, 18, 22, and 24 days after insertion. Two patients with externalized catheters developed superficial infections at 4.5 and 7.5 months, requiring catheter removal and oral antibiotics. At our institution, we use smaller bolus doses of epidural clonidine, and infusions of 20-30 µg per hour for five to seven days. If symptoms are inadequately controlled or recur and prolonged treatment is required, a subcutaneous portal and tunnelled epidural catheter is inserted. The technique of insertion of implantable portals for longterm epidural administration has been previously described 67 . Following treatment and education in hospital, patients self-administer epidural clonidine for several weeks or months until symptoms resolve.
Oral Drugs
A range of systemic drugs have been reported as beneficial in CRPS, but few are supported by large controlled trials. Phenoxybenzamine, an α-receptor antagonist, was trialed in forty soldiers in Lebanon with causalgia and nerve injuries secondary to shrapnel wounds 68 . All patients improved with increasing doses of oral phenoxybenzamine. The authors state that three patients relapsed when the drug was unavailable and improved with resumption of treatment, but this was an unblinded trial with no control group. Calcium channel antagonists have also been used for CRPS, and nifedipine has been reported to improve symptoms in 7 of 13 patients with CRPS 69 .
Anti-convulsant drugs have been used in the management of neuropathic pain, and a recent analysis of randomized controlled trials found supporting evidence for the use of these agents in trigeminal neuralgia, diabetic neuropathy and migraine prophylaxis 70 . Phenytoin has been anecdotally reported to benefit a patient with CRPS 71 . The recently released anticonvulsant gabapentin, which has an improved efficacy-to-toxicity ratio and reduced side-effects, has been found to relieve pain in five patients with CRPS 72 . Meta-analysis of the use of tricyclic antidepressants for chronic pain has shown benefit in patients with diabetic neuropathy, postherpetic neuralgia, tension headache, migraine and atypical facial pain 73 . Tricyclic antidepressants have also been reported to benefit patients with CRPS 20 but these are uncontrolled observations.
Calcitonin and corticosteroids have also been used in some centres 21 . Non-steroidal anti-inflammatory drugs (NSAIDs) may be expected to benefit patients with CRPS as prostaglandins have been shown to mediate peripheral nociceptor activation. However, oral NSAIDs reduced pain in only a minority of patients 20 . Ketorolac, a parenteral NSAID, has been used in intravenous regional blocks 59 .
Intrathecal Therapy
Longterm intrathecal administration of drugs for management of chronic pain has been made possible by the development of implantable pumps and intrathecal catheters. Intrathecal morphine has been reported to benefit patients with intractable CRPS symptoms unresponsive to conventional therapy 74 . In a patient with severe recurrent CRPS associated with massive oedema and blistering of the leg, we administered local anaesthetic via the sideport of an intrathecal pump. The infusion was continued with the patient monitored in the intensive care unit and led to resolution of pain and oedema. Many nonopioid spinal analgesics are being trialed, but their role in CRPS is not yet determined.
Transcutaneous Electrical Nerve Stimulation (TENS)
Reported success of TENS in the management of CRPS varies widely. Wilder et al 20 reported benefit in 50% of children with CRPS, and Kesler et al 75 noted improvement in 9 of 10 children in an uncontrolled retrospective study. As this therapy is non-invasive and has no side-effects apart from occasional skin irritation from the electrodes, a trial of treatment may be worthwhile in longstanding cases. However, in occasional patients stimulation associated with TENS may increase pain.
Dorsal Column Stimulation (DCS)
Dorsal column stimulation is being increasingly used for pain management, as newer electrode technology allows a more widespread and flexible pattern of stimulation. Theories for the efficacy of this treatment are based on the gate control theory with stimulation of large myelinated fibres blocking pain transmission through the spinal cord; or alternatively there may be release of endogenous opioids by stimulation. Law 76 reported 80% success of dorsal column stimulation in 79 cases of CRPS. However, four of the 79 patients had neurological sequelae. It has been proposed that patients with CRPS have greater vascular reactivity and therefore may be more susceptible to spinal artery spasm and subsequent neurological impairment.
Psychological Management
Retrospective psychometric studies have shown higher rates of personality traits such as hypochondriasis, a tendency to somatization, excessive self-control, anxiety and depression in patients with CRPS 13 . However, there are no clear differences from other patients with chronic pain or chronic disease 11 . It must also be remembered that these studies are from pain clinic populations of CRPS patients, and thus are likely to comprise a higher proportion of refractory cases with longstanding disease. Van Houdenhove et al 13 suggested a biopsychosocial hypothesis for the aetiopathogenesis of "RSD". The occurrence of trauma in a psychological context of maladaptive coping personality traits was proposed to result in stress-related sympathetic overactivity and behavioural phenomena which contribute to the initiation and maintenance of the symptom complex. Although this hypothesis has been criticized, it does emphasize the role of multidisciplinary treatment which includes psychiatric and psychological assessment in patients with chronic pain.
Patients with longstanding CRPS often require behavioural and cognitive therapies to break the pattern of disuse and fear of pain. Behavioural responses are particularly important in patients with CRPS, as immobilization and overprotection of the affected limb may produce or exacerbate demineralization, vasomotor changes, oedema and trophic changes. Wilder et al 20 used cognitive-behavioural management in conjunction with physical therapy and TENS in 70 children with CRPS. The program included relaxation training, with or without temperature or electromyographic feedback; cognitivebehavioural therapy to improve skills in the management of stressful situations; and intervention in the behavioural patterns of the family to eliminate reinforcement of behaviours such as repeated avoidance of social obligations, school, and family responsibilities and to promote healthy behaviours such as the use of relaxation techniques and distracting activity to cope with pain. The average time to diagnosis in this group was twelve months, and thus many had prolonged symptoms. Fifty-seven per cent of children reported benefit from behavioural therapy, and continued to use the learned techniques at times of stress and pain. The patients' descriptions of the positive effectiveness of this program were predictive of improved outcomes for pain, function, and the number of autonomic signs present at follow-up.
CONCLUSION
The IASP consensus conference has brought together expert opinion in relation to Complex Regional Pain Syndromes. It is recognized that validated scientific fact is still lacking in some areas of pathophysiology and treatment 70 , and many hypotheses remain to be confirmed or modified as further information becomes available. Animal and clinical studies support the role of the sympathetic nervous system in the generation and maintenance of pain states, although the factors initiating sympathetically maintained pain remain unclear. The diagnosis of CRPS should be based on clinical symptoms and signs, with additional information being provided by carefully performed and interpreted diagnostic and therapeutic tests.The adoption of universal terminology and diagnostic criteria should improve recognition, reporting, and outcome assessment.
Early recognition and management of CRPS requires collaboration between primary care specialists and physicians involved in pain management. A large body of clinical experience supports the need for early intervention including sympathetic blockade to reduce pain and autonomic dysfunction and allow active mobilization. At this stage, further scientific data is required to confirm the appropriate timing, and to determine the relative merits of different sympatholytic techniques. The designation Complex Regional Pain Syndrome, which does not imply an underlying pathophysiology, reinforces the view that multimodal treatment is required and sympatholytic procedures should not be performed in isolation. Ongoing assessment of function as well as pain is required to reduce the secondary effects of disuse in patients with longstanding symptoms. Referral to a specialist pain management centre should be considered for patients with ongoing or severe signs, as more invasive treatments may be required in conjunction with a multi-disciplinary pain management plan.
